FAL
0.375
97.4%
HLX
0.001
-50%
ATH
0.015
66.7%
TMK
0.002
-33.3%
GGE
0.003
50%
BMG
0.007
-30%
RMI
0.02
42.9%
ALR
0.003
-25%
CMB
0.3
39.5%
BLZ
0.003
-25%
MGU
0.008
33.3%
GTR
0.003
-25%
CMG
0.13
31.3%
PRS
0.018
-21.7%
BCA
0.235
30.6%
ADD
0.02
-20%
PGY
0.013
30%
VEN
0.004
-20%
GLA
0.009
28.6%
CLG
0.046
-19.3%
NPM
0.027
28.6%
G88
0.009
-18.2%
PH2
0.105
28%
CDE
0.023
-17.9%
SRL
1.345
27.5%
IPB
0.005
-16.7%
GBZ
0.019
26.7%
SER
0.005
-16.7%
FHS
0.005
25%
TX3DA
0.1
-16.7%
LKY
0.085
25%
IBX
0.016
-15.8%
EGR
0.32
23.1%
SCN
0.017
-15%
JGH
0.032
23.1%
VUL
3.48
-13%
NSB
0.16
23.1%
RON
0.135
-12.9%
ILU
4.89
22.9%
W2V
0.007
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Recce Pharmaceuticals (ASX:RCE) reveals successful batch completion under Good Manufacturing Practices

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), a company developing a New Class of Synthetic Anti-Infectives, announces successful batch completion under Good Manufacturing Practices (GMP) for RECCE® 327 with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.

Highlights

  • Successful production of 5,000 x RECCE® 327 (R327) doses per week under GMP campaign.
  • R327 manufactured under GMP standards in support of present Phase I, Phase II and anticipated Registrational Phase III clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration.

 

Commentary 

Recce Pharmaceuticals’ Head of Manufacturing Arthur Kollaras said “We are thrilled to
announce the successful batch completion of human pharmaceutical grade R327, representing
a crucial step forward in our mission to address the global threat of antimicrobial resistance.”